Cancer Immunology Reserch

Cancer Immunol Res. 2026 Jan 20. doi: 10.1158/2326-6066.CIR-25-0695. Online ahead of print. ABSTRACT GPR84 is a medium-chain free fatty acid receptor predominantly expressed in myeloid cells. Previous studies have identified GPR84 as an enhancer of the pro-inflammatory myeloid cell responses and a regulator of metabolic homeostasis. However, the role of GPR84 in T cell function … Read more

Cancer Immunol Res. 2026 Jan 15. doi: 10.1158/2326-6066.CIR-24-1159. Online ahead of print. ABSTRACT Tumor-associated macrophages (TAMs) represent the main immune population infiltrating cancers, and their abundance is generally correlated with a poor prognosis. The acquisition of protumor properties by TAMs involves several mechanisms, including expression of immunosuppressive enzymes. In this study, we explored the role … Read more

Cancer Immunol Res. 2026 Jan 14:OF1-OF2. doi: 10.1158/2326-6066.CIR-25-1596. Online ahead of print. ABSTRACT Oncolytic viruses (OV) are thought to mediate antitumor activity by killing tumor cells and inducing antitumor immunity, but how this happens is not well understood. In this issue, Ludwig and colleagues show that PVSRIPO, an oncolytic poliovirus being developed for glioblastoma, may … Read more

Cancer Immunol Res. 2026 Jan 13:OF1-OF2. doi: 10.1158/2326-6066.CIR-25-1344. Online ahead of print. ABSTRACT Adoptive T-cell therapies have shown limited efficacy against solid tumors, so new approaches are required. In this issue, Chantzoura and colleagues describe MiNK-215, a novel allogeneic fibroblast activation protein-targeting chimeric antigen receptor invariant NK T-cell therapy engineered to secrete IL15. They show … Read more

Cancer Immunol Res. 2026 Jan 12. doi: 10.1158/2326-6066.CIR-25-1126. Online ahead of print. ABSTRACT Combination vaccine and checkpoint inhibitor therapy has previously demonstrated immunologic responses in patients with pancreatic ductal adenocarcinoma (PDAC), although with limited efficacy. An urgent need to augment responses has warranted a deeper understanding of how each treatment modality contributes to the overall … Read more

Cancer Immunol Res. 2026 Jan 12. doi: 10.1158/2326-6066.CIR-25-0545. Online ahead of print. ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains highly lethal and has poor immunogenicity, warranting the use of vaccines to guide and recruit the immune response. Building on prior efforts to achieve clinical immunotherapeutic responses against PDAC, we conducted a phase II study (NCT03190265) that … Read more

Cancer Immunol Res. 2026 Jan 12:OF1-OF8. doi: 10.1158/2326-6066.CIR-25-1479. Online ahead of print. ABSTRACT The transition from trainee to independent investigator is one of the most challenging and formative phases of a scientific career. It requires not only scientific expertise but also the skills to lead, mentor, manage, and communicate effectively. The Arthur and Sandra Irving … Read more

Cancer Immunol Res. 2026 Jan 9. doi: 10.1158/2326-6066.CIR-25-0873. Online ahead of print. ABSTRACT Pseudomonas aeruginosa infection is still a serious problem among immunocompromised patients who have advanced urinary tract malignancies, yet the impact of P. aeruginosa on disease progression remains poorly defined. Here, we show that urinary tract infections (UTI) caused by P. aeruginosa exacerbated … Read more

Cancer Immunol Res. 2026 Jan 9:OF1-OF11. doi: 10.1158/2326-6066.CIR-25-1018. Online ahead of print. ABSTRACT The gut microbiome has emerged as a modulator of both cancer progression and patient responses to therapies like immune checkpoint inhibitors (ICI). Recent evidence highlights microbially derived metabolites as key regulators of immune response and tumor microenvironment dynamics. This review explores the … Read more

Cancer Immunol Res. 2026 Jan 8. doi: 10.1158/2326-6066.CIR-25-0880. Online ahead of print. ABSTRACT The ability of interleukin-12 (IL-12) to stimulate production of interferon gamma (IFN-γ) suggested it might improve the efficacy of low dose interferon alpha (IFN-α). In this phase II trial, patients with metastatic malignant melanoma were administered recombinant human (rh) IL-12 followed by … Read more